More Stories

Informist, Tuesday, Aug. 4, 2026

 

Please click here to read all liners published on this story

--Alembic Pharma Apr-Jun consol net profit INR 1.73 bln
--Analysts saw Alembic Pharma Apr-Jun consol net profit at INR 1.53 bln
--Alembic Pharma Apr-Jun consol revenue INR 21.50 bln
--Analysts saw Alembic Pharma Apr-Jun consol revenue at INR 19.02 bln
--Alembic Pharma Apr-Jun consol PAT INR 1.73 bln vs INR 1.54 bln year ago
--Alembic Pharma Q1 consol revenue INR 21.50 bln vs INR 17.11 bln yr ago
--Alembic Pharma Apr-Jun consol operating margin 16.18% vs 16.84% year ago
--Alembic Pharma Apr-Jun EBITDA margin 16% vs 17% year ago 
--Alembic Pharma Apr-Jun consol gross margin 71% vs 76% year ago 
--Alembic Pharma R&D expense 9% of consol revenue in Q1 vs 8% year ago 
--Alembic Pharma Apr-Jun India formulation sales INR 6.42 bln, up 7% on year 
--Alembic Pharma Apr-Jun US formulation sales INR 7.78 bln, up 49% on year 
--Alembic Pharma Apr-Jun API business sales INR 3.46 bln, up 33% on year
--Alembic Pharma: Expect to launch over 15 products in US in FY27 

 

By Pratyush Kumar

 

MUMBAI – Alembic Pharmaceuticals Ltd. reported a jump in revenue from operations for the June quarter but the rise in total expenses outpaced the sales growth, preventing the net profit from growing in line with revenues. Both the revenue and the profit beat analyst estimates by a wide margin, however.

 

The medicine maker's consolidated net profit for the June quarter rose 12% on year to INR 1.73 billion. For the year-ago quarter, it had reported a net profit of INR 1.54 billion. Analysts had expected the company to report a net profit of INR 1.53 billion.

 

Alembic Pharma's consolidated revenue from operations for the June quarter was INR 21.50 billion, up 26% from INR 17.10 billion for the corresponding quarter a year ago. Analysts had expected the company to report net sales of INR 19.02 billion.

 

The company's total expenses grew 27% on year to INR 19.43 billion. The expenses rose mainly on account of a 21% rise in other expenses and a 20% increase in cost of materials consumed. Other expenses, the biggest expense head for the company, accounted for more than 37% of the total expenses.

 

At 1445 IST, shares of the company were at INR 806.3 apiece on the National Stock Exchange, up marginally from Monday. The stock dipped nearly 2?ter the company detailed its June quarter earnings. It eventually closed at INR 809.40, up 0.5% from Monday.

 

The company's earnings before interest, tax, depreciation, and amortisation margin for the June quarter contracted 100 basis points to 16% from 17% reported in the year-ago quarter. The EBITDA, before research and development expenses, increased to INR 5.23 billion. The company spent 9% of the consolidated revenue for the June quarter on R&D, up from 8% reported a year ago.

 

"Performance during the quarter was driven by healthy volume growth, successful new product launches, and continued execution across key markets," Pranav Amin, managing director of the company, said. "The US business delivered strong momentum and the rest of the markets also recorded steady growth."

 

Alembic Pharma's India formulation sales for the June quarter rose 7% on year to INR 6.42 billion. The US formulation sales grew 49% to INR 7.78 billion. The company's active pharmaceutical ingredient business grew 33% on year to INR 3.46 billion. The pharmaceutical company introduced three new products in India during the quarter and made seven launches in the US market.  End

 

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.